| Hydralazine, sold under the brand name Apresoline among others, is a medication used to treat high blood pressure and heart failure. This includes high blood pressure in pregnancy and very high blood pressure resulting in symptoms. It has been found to be particularly useful in heart failure, together with isosorbide dinitrate, for treatment of people of African descent. It is given by mouth or by injection into a vein. Effects usually begin around 15 minutes and last up to six hours.
Common side effects include headache and fast heart rate. It is not recommended in people with coronary artery disease or in those with rheumatic heart disease that affects the mitral valve. In those with kidney disease a low dose is recommended. Hydralazine is in the vasodilator family of medications, so it is believed to work by causing the dilation of blood vessels.
Hydralazine was discovered while scientists at Ciba were looking for a treatment for malaria. It was patented in 1949. It is on the World Health Organization's List of Essential Medicines. In 2022, it was the 121st most commonly prescribed medication in the United States, with more than 5 million prescriptions. |
|
Read full article at Wikipedia
|
InChI=1S/C31H43N3O8/c1- 8-12-33-26-21-13-17(2)14-25(41-7)27(36)19(4)15-20(5)29(42-31(32)39)24(40-6)11-9-10-18(3)30(38)34-22(28(21)37)16-23(26)35/h8-11,15-17,19,24-25,27,29,33,36H,1,12-14H2,2-7H3,(H2,32,39)(H,34,38)/b11-9-,18-10+,20-15+/t17-,19+,24+,25+,27-,29+/m1/s1 |
| AYUNIORJHRXIBJ-TXHRRWQRSA-N |
| C=1C(C(=C2C(C1NC(=O)C(C)=CC=C[C@@H]([C@@H](OC(N)=O)C(C)=C[C@@H]([C@H]([C@H](C[C@@H](C2)C)OC)O)C)OC)=O)NCC=C)=O |
|
|
Bronsted base
A molecular entity capable of accepting a hydron from a donor (Bronsted acid).
(via organic amino compound )
|
|
|
Hsp90 inhibitor
An EC 3.6.4.10 (non-chaperonin molecular chaperone ATPase) inhibitor that blocks the action of heat shock protein 90.
apoptosis inducer
Any substance that induces the process of apoptosis (programmed cell death) in multi-celled organisms.
|
|
|
antineoplastic agent
A substance that inhibits or prevents the proliferation of neoplasms.
|
|
View more via ChEBI Ontology
|
(4E,6Z,8S,9S,10E,12S,13R,14S,16R)-13-hydroxy-8,14-dimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-19-(prop-2-en-1-ylamino)-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaen-9-yl carbamate
|
|
tanespimycin
|
WHO MedNet
|
tanespimycina
|
WHO MedNet
|
tanespimycine
|
WHO MedNet
|
tanespimycinum
|
WHO MedNet
|
|
17-(Allylamino)-17-demethoxygeldanamycin
|
ChemIDplus
|
|
17-(Allylamino)geldanamycin
|
ChemIDplus
|
|
17-AAG
|
ChEBI
|
|
17-allylaminogeldanamycin
|
ChEBI
|
|
17-demethoxy-17-(2-propenylamino)geldanamycin
|
ChemIDplus
|
|
17-Demethoxy-17-allylamino geldanamycin
|
ChemIDplus
|
|
17-N-allylamino-17-demethoxygeldanamycin
|
ChEBI
|
|
17AAG
|
ChEBI
|
|
NSC 330507
|
ChemIDplus
|
|
NSC-330507
|
ChemIDplus
|
|
7402240
|
Reaxys Registry Number
|
Reaxys
|
|
75747-14-7
|
CAS Registry Number
|
ChemIDplus
|
|
